Hambruch, Eva

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology

Liver Disease and TransplantationLiver physiology and pathology

Cited by 178

Nonsteroidal FXR Ligands: Current Status and Clinical Applications

Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology

Drug Transport and Resistance MechanismsLiver Disease Diagnosis and Treatment

Cited by 83

The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model

Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., et al. (2021) · Biomedicines

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 70

Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties

Kinzel, O., Steeneck, C., Schlüter, T., Schulz, A., Gege, C., Hahn, U., Hambruch, E., Hornberger, M., Spalwisz, A., Frick, K., et al. (2016) · Bioorganic & Medicinal Chemistry Letters

Drug Transport and Resistance MechanismsPeroxisome Proliferator-Activated Receptors

Cited by 35

On the Pharmacology of Farnesoid X Receptor Agonists: Give me an "A", Like in "Acid"

Hambruch, E., Kinzel, O., & Kremoser, C. (2016) · Nuclear Receptor Research

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 3